{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:09:29Z","timestamp":1778296169875,"version":"3.51.4"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10072-026-08964-y","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:10:19Z","timestamp":1773965419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Italian recommendations for the diagnosis and treatment of myasthenia gravis"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8813-2272","authenticated-orcid":false,"given":"Laura","family":"Fionda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo Emilio","family":"Alboini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Antozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico Marco","family":"Bonifati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Damato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Habetswallner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Inghilleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelangelo","family":"Maestri Tassoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Massa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Pegoraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Pino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Evoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"8964_CR1","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","volume":"40","author":"A Evoli","year":"2019","unstructured":"Evoli A, Antonini G, Antozzi C et al (2019) Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol Sci 40:1111\u20131124. https:\/\/doi.org\/10.1007\/s10072-019-03746-1","journal-title":"Neurol Sci"},{"key":"8964_CR2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"8964_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"8964_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard","year":"2023","unstructured":"Howard JF, Bresch S, Genge A et al (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22:395\u2013406. https:\/\/doi.org\/10.1016\/S1474-4422(23)00080-7","journal-title":"Lancet Neurol"},{"key":"8964_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J et al (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22:383\u2013394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7","journal-title":"Lancet Neurol"},{"key":"8964_CR6","doi-asserted-by":"publisher","first-page":"e70158","DOI":"10.1111\/ene.70158","volume":"32","author":"TH Vu","year":"2025","unstructured":"Vu TH, Mantegazza R, Annane D et al (2025) Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension. Eur J Neurol 32:e70158. https:\/\/doi.org\/10.1111\/ene.70158","journal-title":"Eur J Neurol"},{"key":"8964_CR7","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A et al (2023) Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord 16:17562864231213240. https:\/\/doi.org\/10.1177\/17562864231213240","journal-title":"Ther Adv Neurol Disord"},{"key":"8964_CR8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.21037\/atm-19-363","volume":"11","author":"Y Li","year":"2023","unstructured":"Li Y, Peng Y, Yang H (2023) Serological diagnosis of myasthenia gravis and its clinical significance. Ann Transl Med 11:290. https:\/\/doi.org\/10.21037\/atm-19-363","journal-title":"Ann Transl Med"},{"key":"8964_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 96:114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"8964_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100846","author":"Z Li","year":"2023","unstructured":"Li Z, Zhang C, Chang T et al (2023) A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study. Lancet Reg Health \u2013 Western Pac. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100846. 38:","journal-title":"Lancet Reg Health \u2013 Western Pac"},{"key":"8964_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R et al (2022) Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve 65:630\u2013639. https:\/\/doi.org\/10.1002\/mus.27476","journal-title":"Muscle Nerve"},{"key":"8964_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/mus.28417","volume":"72","author":"K Ruzhansky","year":"2025","unstructured":"Ruzhansky K, Li Y, Wolfe GI et al (2025) Standardization of Myasthenia Gravis Outcome Measures in Clinical Practice: A Report of the MGFA Task Force. Muscle Nerve 72:56\u201365. https:\/\/doi.org\/10.1002\/mus.28417","journal-title":"Muscle Nerve"},{"key":"8964_CR13","doi-asserted-by":"crossref","unstructured":"Sanders DB, Wolfe GI, Benatar M (2016) International consensus guidance for management of myasthenia gravis","DOI":"10.1212\/WNL.0000000000002790"},{"key":"8964_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","volume":"36","author":"C Barnett","year":"2018","unstructured":"Barnett C, Herbelin L, Dimachkie MM, Barohn RJ (2018) Measuring Clinical Treatment Response in Myasthenia Gravis. Neurol Clin 36:339\u2013353. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.006","journal-title":"Neurol Clin"},{"key":"8964_CR15","doi-asserted-by":"publisher","first-page":"596382","DOI":"10.3389\/fneur.2020.596382","volume":"11","author":"JLS Thomsen","year":"2020","unstructured":"Thomsen JLS, Andersen H (2020) Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis. Front Neurol 11:596382. https:\/\/doi.org\/10.3389\/fneur.2020.596382","journal-title":"Front Neurol"},{"key":"8964_CR16","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","volume":"267","author":"J Vissing","year":"2020","unstructured":"The REGAIN study group, Vissing J, Jacob S et al (2020) Minimal symptom expression\u2019 in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol 267:1991\u20132001. https:\/\/doi.org\/10.1007\/s00415-020-09770-y","journal-title":"J Neurol"},{"key":"8964_CR17","doi-asserted-by":"publisher","first-page":"114603","DOI":"10.1016\/j.intimp.2025.114603","volume":"154","author":"J Chen","year":"2025","unstructured":"Chen J, Zhu X, Zhou H et al (2025) Efficacy of multi-cycle Efgartigimod in achieving minimal symptom expression in myasthenia gravis: A comparative multi-center study. Int Immunopharmacol 154:114603. https:\/\/doi.org\/10.1016\/j.intimp.2025.114603","journal-title":"Int Immunopharmacol"},{"key":"8964_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2012.06812.x","volume":"1274","author":"TM Burns","year":"2012","unstructured":"Burns TM (2012) The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Ann N Y Acad Sci 1274:99\u2013106. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06812.x","journal-title":"Ann N Y Acad Sci"},{"key":"8964_CR19","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1212\/WNL.0000000000004676","volume":"89","author":"C Barnett","year":"2017","unstructured":"Barnett C, Bril V, Kapral M et al (2017) Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency. Neurology 89:2357\u20132364. https:\/\/doi.org\/10.1212\/WNL.0000000000004676","journal-title":"Neurology"},{"key":"8964_CR20","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s40120-023-00464-x","volume":"12","author":"A Regnault","year":"2023","unstructured":"Regnault A, Morel T, de la Loge C et al (2023) Measuring overall severity of myasthenia gravis (MG): evidence for the added value of the MG symptoms PRO. Neurol Ther 12:1573\u20131590. https:\/\/doi.org\/10.1007\/s40120-023-00464-x","journal-title":"Neurol Ther"},{"key":"8964_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/mus.25720","volume":"57","author":"A Abraham","year":"2018","unstructured":"Abraham A, Breiner A, Barnett C et al (2018) The utility of a single simple question in the evaluation of patients with myasthenia gravis. Muscle Nerve 57:240\u2013244. https:\/\/doi.org\/10.1002\/mus.25720","journal-title":"Muscle Nerve"},{"key":"8964_CR22","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1111\/ene.14397","volume":"27","author":"D Menon","year":"2020","unstructured":"Menon D, Barnett C, Bril V (2020) Comparison of the single simple question and the patient acceptable symptom state in myasthenia gravis. Eur J Neurol 27:2286\u20132291. https:\/\/doi.org\/10.1111\/ene.14397","journal-title":"Eur J Neurol"},{"key":"8964_CR23","doi-asserted-by":"publisher","first-page":"e70262","DOI":"10.1111\/ene.70262","volume":"32","author":"G Spagni","year":"2025","unstructured":"Spagni G, Verza MU, Cornacchini S et al (2025) Validation of the Patient-Acceptable Symptom State Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study. Eur J Neurol 32:e70262. https:\/\/doi.org\/10.1111\/ene.70262","journal-title":"Eur J Neurol"},{"key":"8964_CR24","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA et al (2015) Validity and reliability of the US National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1:1051\u20131059. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2639","journal-title":"JAMA Oncol"},{"key":"8964_CR25","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","volume":"54","author":"TM Burns","year":"2016","unstructured":"Burns TM, Sadjadi R, Utsugisawa K et al (2016) International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve 54:1015\u20131022. https:\/\/doi.org\/10.1002\/mus.25198","journal-title":"Muscle Nerve"},{"key":"8964_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A et al (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"8964_CR27","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/mus.25438","volume":"55","author":"MH Rivner","year":"2017","unstructured":"Rivner MH, Liu S, Quarles B et al (2017) Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients. Muscle Nerve 55:430\u2013432. https:\/\/doi.org\/10.1002\/mus.25438","journal-title":"Muscle Nerve"},{"key":"8964_CR28","doi-asserted-by":"publisher","first-page":"577895","DOI":"10.1016\/j.jneuroim.2022.577895","volume":"368","author":"CJ Klein","year":"2022","unstructured":"Klein CJ, Beecher G, Lamb C et al (2022) LRP4-IgG service line testing in seronegative myasthenia gravis and controls. J Neuroimmunol 368:577895. https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577895","journal-title":"J Neuroimmunol"},{"key":"8964_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/cells8070671","volume":"8","author":"I Koneczny","year":"2019","unstructured":"Koneczny I, Herbst R (2019) Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture. Cells 8:671. https:\/\/doi.org\/10.3390\/cells8070671","journal-title":"Cells"},{"key":"8964_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ane.12271","volume":"130","author":"P Szczudlik","year":"2014","unstructured":"Szczudlik P, Szyluk B, Lipowska M et al (2014) Antititin antibody in early- and late-onset myasthenia gravis. Acta Neurol Scand 130:229\u2013233. https:\/\/doi.org\/10.1111\/ane.12271","journal-title":"Acta Neurol Scand"},{"key":"8964_CR31","doi-asserted-by":"publisher","first-page":"113748","DOI":"10.1016\/j.jim.2024.113748","volume":"534","author":"A Mariscal","year":"2024","unstructured":"Mariscal A, Mart\u00ednez C, Goethals L et al (2024) Modified radioimmunoassay versus ELISA to quantify anti-acetylcholine receptor antibodies in a mouse model of myasthenia gravis. J Immunol Methods 534:113748. https:\/\/doi.org\/10.1016\/j.jim.2024.113748","journal-title":"J Immunol Methods"},{"key":"8964_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/25785826.2025.2472449","volume":"48","author":"S Suzuki","year":"2025","unstructured":"Suzuki S (2025) Pathogenesis and detection methods of anti-acetylcholine receptor antibodies in myasthenia gravis. Immunological Med 48:117\u2013123. https:\/\/doi.org\/10.1080\/25785826.2025.2472449","journal-title":"Immunological Med"},{"key":"8964_CR33","doi-asserted-by":"publisher","first-page":"110826","DOI":"10.1016\/j.clinbiochem.2024.110826","volume":"133\u2013134","author":"A Mousavi","year":"2024","unstructured":"Mousavi A, Kumar P, Frykman H (2024) The changing landscape of autoantibody testing in myasthenia gravis in the setting of novel drug treatments. Clin Biochem 133\u2013134:110826. https:\/\/doi.org\/10.1016\/j.clinbiochem.2024.110826","journal-title":"Clin Biochem"},{"key":"8964_CR34","doi-asserted-by":"publisher","first-page":"e213498","DOI":"10.1212\/WNL.0000000000213498","volume":"104","author":"P Zara","year":"2025","unstructured":"Zara P, Chessa P, Deiana GA et al (2025) Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice. Neurology 104:e213498. https:\/\/doi.org\/10.1212\/WNL.0000000000213498","journal-title":"Neurology"},{"key":"8964_CR35","doi-asserted-by":"publisher","first-page":"e16435","DOI":"10.1111\/ene.16435","volume":"31","author":"S Falso","year":"2024","unstructured":"Falso S, Marini S, Carrozza C et al (2024) Concordance between radioimmunoassay and fixed cell-based assay in subjects without myasthenia gravis: optimizing the diagnostic approach. Eur J Neurol 31:e16435. https:\/\/doi.org\/10.1111\/ene.16435","journal-title":"Eur J Neurol"},{"key":"8964_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ (2020) Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol 11:212. https:\/\/doi.org\/10.3389\/fimmu.2020.00212","journal-title":"Front Immunol"},{"key":"8964_CR37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s12264-012-1256-0","volume":"28","author":"Q-G Shi","year":"2012","unstructured":"Shi Q-G, Wang Z-H, Ma X-W et al (2012) Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis. Neurosci Bull 28:469\u2013474. https:\/\/doi.org\/10.1007\/s12264-012-1256-0","journal-title":"Neurosci Bull"},{"key":"8964_CR38","doi-asserted-by":"publisher","first-page":"120084","DOI":"10.1016\/j.jns.2021.120084","volume":"432","author":"A Mirian","year":"2022","unstructured":"Mirian A, Nicolle MW, Edmond P, Budhram A (2022) Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis. J Neurol Sci 432:120084. https:\/\/doi.org\/10.1016\/j.jns.2021.120084","journal-title":"J Neurol Sci"},{"key":"8964_CR39","doi-asserted-by":"publisher","first-page":"e200038","DOI":"10.1212\/NXI.0000000000200038","volume":"10","author":"G Spagni","year":"2023","unstructured":"Spagni G, Gastaldi M, Businaro P et al (2023) Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis. Neurol Neuroimmunol Neuroinflammation 10:e200038. https:\/\/doi.org\/10.1212\/NXI.0000000000200038","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"8964_CR40","doi-asserted-by":"publisher","first-page":"1459423","DOI":"10.3389\/fimmu.2025.1459423","volume":"16","author":"JS Tzartos","year":"2025","unstructured":"Tzartos JS, Vakrakou AG, Karagiorgou K et al (2025) Efficiency of cell-based assays in detecting AChR antibodies in myasthenia gravis sera with low antibody concentrations as determined by radioimmunoprecipitation assay. Front Immunol 16:1459423. https:\/\/doi.org\/10.3389\/fimmu.2025.1459423","journal-title":"Front Immunol"},{"key":"8964_CR41","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/jnnp-2022-329284","volume":"93","author":"V Damato","year":"2022","unstructured":"Damato V, Spagni G, Monte G et al (2022) Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry 93:995\u20131000. https:\/\/doi.org\/10.1136\/jnnp-2022-329284","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8964_CR42","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1212\/NXI.0000000000000357","volume":"4","author":"S Huda","year":"2017","unstructured":"Huda S, Waters P, Woodhall M et al (2017) IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG. Neurol Neuroimmunol Neuroinflamm 4:e357. https:\/\/doi.org\/10.1212\/NXI.0000000000000357","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"8964_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.104468","volume":"44","author":"A Evoli","year":"2024","unstructured":"Evoli A, Palace J, Spagni G et al (2024) 275th ENMC international workshop: seronegative myasthenia gravis: an update paradigm for diagnosis and management, 9\u201311 February 2024, Hoofddorp, the Netherlands. Neuromuscul Disord 44:104468. https:\/\/doi.org\/10.1016\/j.nmd.2024.104468","journal-title":"Neuromuscul Disord"},{"key":"8964_CR44","doi-asserted-by":"publisher","first-page":"e2249947","DOI":"10.1002\/eji.202249947","volume":"54","author":"SM Wemlinger","year":"2024","unstructured":"Wemlinger SM, Cambier JC (2024) Therapeutic tactics for targeting B lymphocytes in autoimmunity and cancer. Eur J Immunol 54:e2249947. https:\/\/doi.org\/10.1002\/eji.202249947","journal-title":"Eur J Immunol"},{"key":"8964_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.13501","volume":"1412","author":"M Benatar","year":"2018","unstructured":"Benatar M, Howard JF, Barohn R et al (2018) Learning from the past: reflections on recently completed myasthenia gravis trials. Ann N Y Acad Sci 1412:5\u201313. https:\/\/doi.org\/10.1111\/nyas.13501","journal-title":"Ann N Y Acad Sci"},{"key":"8964_CR46","doi-asserted-by":"publisher","unstructured":"Dodd KC, Clay FJ, Forbes A-M et al (2025) Rituximab for myasthenia gravis. Cochrane Database. https:\/\/doi.org\/10.1002\/14651858.cd014574.pub2. of Systematic Reviews 2025:","DOI":"10.1002\/14651858.cd014574.pub2"},{"key":"8964_CR47","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A et al (2022) Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. JAMA Neurol 79:1105. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"key":"8964_CR48","doi-asserted-by":"publisher","first-page":"e70418","DOI":"10.1111\/ene.70418","volume":"32","author":"J Wu","year":"2025","unstructured":"Wu J, Eriksson-Dufva A, Budzianowska A et al (2025) Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical Trial. Eur J Neurol 32:e70418. https:\/\/doi.org\/10.1111\/ene.70418","journal-title":"Eur J Neurol"},{"key":"8964_CR49","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1007\/s00415-022-11048-4","volume":"269","author":"Y Du","year":"2022","unstructured":"Du Y, Li C, Hao Y et al (2022) Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis. J Neurol 269:4229\u20134240. https:\/\/doi.org\/10.1007\/s00415-022-11048-4","journal-title":"J Neurol"},{"key":"8964_CR50","doi-asserted-by":"publisher","first-page":"577528","DOI":"10.1016\/j.jneuroim.2021.577528","volume":"354","author":"H Li","year":"2021","unstructured":"Li H, Huang Z, Jia D et al (2021) Low-dose rituximab treatment for new-onset generalized myasthenia gravis. J Neuroimmunol 354:577528. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577528","journal-title":"J Neuroimmunol"},{"key":"8964_CR51","doi-asserted-by":"publisher","first-page":"1439899","DOI":"10.3389\/fneur.2024.1439899","volume":"15","author":"X Yang","year":"2024","unstructured":"Yang X, Zhang W, Guo J et al (2024) Efficacy and safety of low-dose rituximab in the treatment of myasthenia gravis: a systemic review and meta-analysis. Front Neurol 15:1439899. https:\/\/doi.org\/10.3389\/fneur.2024.1439899","journal-title":"Front Neurol"},{"key":"8964_CR52","doi-asserted-by":"publisher","first-page":"725700","DOI":"10.3389\/fneur.2021.725700","volume":"12","author":"X Feng","year":"2021","unstructured":"Feng X, Song Z, Wu M et al (2021) Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis. Front Neurol 12:725700. https:\/\/doi.org\/10.3389\/fneur.2021.725700","journal-title":"Front Neurol"},{"key":"8964_CR53","doi-asserted-by":"publisher","first-page":"736190","DOI":"10.3389\/fneur.2021.736190","volume":"12","author":"C Zhao","year":"2021","unstructured":"Zhao C, Pu M, Chen D et al (2021) Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis. Front Neurol 12:736190. https:\/\/doi.org\/10.3389\/fneur.2021.736190","journal-title":"Front Neurol"},{"key":"8964_CR54","doi-asserted-by":"publisher","first-page":"1275533","DOI":"10.3389\/fneur.2023.1275533","volume":"14","author":"A Vesperinas-Castro","year":"2023","unstructured":"Vesperinas-Castro A, Cort\u00e9s-Vicente E (2023) Rituximab treatment in myasthenia gravis. Front Neurol 14:1275533. https:\/\/doi.org\/10.3389\/fneur.2023.1275533","journal-title":"Front Neurol"},{"key":"8964_CR55","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/acn3.564","volume":"5","author":"E Cort\u00e9s-Vicente","year":"2018","unstructured":"Cort\u00e9s-Vicente E, Rojas-Garcia R, D\u00edaz-Manera J et al (2018) The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Ann Clin Transl Neurol 5:710\u2013716. https:\/\/doi.org\/10.1002\/acn3.564","journal-title":"Ann Clin Transl Neurol"},{"key":"8964_CR56","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir MK, Hobson-Webb LD, Benatar M et al (2017) Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology 89:1069\u20131077. https:\/\/doi.org\/10.1212\/WNL.0000000000004341","journal-title":"Neurology"},{"key":"8964_CR57","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","volume":"266","author":"R Topakian","year":"2019","unstructured":"Topakian R, Zimprich F, Iglseder S et al (2019) High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol 266:699\u2013706. https:\/\/doi.org\/10.1007\/s00415-019-09191-6","journal-title":"J Neurol"},{"key":"8964_CR58","doi-asserted-by":"publisher","first-page":"1624038","DOI":"10.3389\/fimmu.2025.1624038","volume":"16","author":"F Li","year":"2025","unstructured":"Li F, Zhang Z, Ma T et al (2025) A pilot study of the immunological profile and efficacy of rituximab in muscle-specific kinase antibody-positive myasthenia gravis. Front Immunol 16:1624038. https:\/\/doi.org\/10.3389\/fimmu.2025.1624038","journal-title":"Front Immunol"},{"key":"8964_CR59","doi-asserted-by":"publisher","first-page":"7219","DOI":"10.1038\/s41598-025-90937-w","volume":"15","author":"S Chayanopparat","year":"2025","unstructured":"Chayanopparat S, Banyatcharoen P, Jitprapaikulsan J et al (2025) Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis. Sci Rep 15:7219. https:\/\/doi.org\/10.1038\/s41598-025-90937-w","journal-title":"Sci Rep"},{"key":"8964_CR60","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3233\/JND-180300","volume":"5","author":"O Landon-Cardinal","year":"2018","unstructured":"Landon-Cardinal O, Friedman D, Guiguet M et al (2018) Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis. J Neuromuscul Dis 5:241\u2013249. https:\/\/doi.org\/10.3233\/JND-180300","journal-title":"J Neuromuscul Dis"},{"key":"8964_CR61","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136471","volume":"5","author":"R Jiang","year":"2020","unstructured":"Jiang R, Fichtner ML, Hoehn KB et al (2020) Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses. JCI Insight 5:e136471. https:\/\/doi.org\/10.1172\/jci.insight.136471","journal-title":"JCI Insight"},{"key":"8964_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00776","volume":"11","author":"ML Fichtner","year":"2020","unstructured":"Fichtner ML, Jiang R, Bourke A et al (2020) Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol 11:776. https:\/\/doi.org\/10.3389\/fimmu.2020.00776","journal-title":"Front Immunol"},{"key":"8964_CR63","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jneuroim.2016.07.009","volume":"298","author":"C Lebrun","year":"2016","unstructured":"Lebrun C, Bourg V, Bresch S et al (2016) Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis. J Neuroimmunol 298:79\u201381. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.07.009","journal-title":"J Neuroimmunol"},{"key":"8964_CR64","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1007\/s13311-021-01006-9","volume":"18","author":"C Ruetsch-Chelli","year":"2021","unstructured":"Ruetsch-Chelli C, Bresch S, Seitz-Polski B et al (2021) Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis. Neurotherapeutics 18:938\u2013948. https:\/\/doi.org\/10.1007\/s13311-021-01006-9","journal-title":"Neurotherapeutics"},{"key":"8964_CR65","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK, Waheed W, Howard DB (2017) Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 56:185\u2013196. https:\/\/doi.org\/10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"key":"8964_CR66","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/1744666X.2019.1562905","volume":"15","author":"F Paul","year":"2019","unstructured":"Paul F, Cartron G (2019) Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol 15:383\u2013389. https:\/\/doi.org\/10.1080\/1744666X.2019.1562905","journal-title":"Expert Rev Clin Immunol"},{"key":"8964_CR67","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000042972","volume":"104","author":"C-H Hou","year":"2025","unstructured":"Hou C-H, Chang H, Ong Y-C et al (2025) Risk factors and clinical consequences of rituximab infusion-related reactions. Medicine (Baltimore) 104:e42972. https:\/\/doi.org\/10.1097\/MD.0000000000042972","journal-title":"Medicine (Baltimore)"},{"key":"8964_CR68","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","volume":"130","author":"TS Athni","year":"2023","unstructured":"Athni TS, Barmettler S (2023) Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Ann Allergy Asthma Immunol 130:699\u2013712. https:\/\/doi.org\/10.1016\/j.anai.2023.01.018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"8964_CR69","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.nmd.2022.06.006","volume":"32","author":"M Caballero-\u00c1vila","year":"2022","unstructured":"Caballero-\u00c1vila M, \u00c1lvarez-Velasco R, Moga E et al (2022) Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia. Neuromuscul Disord 32:664\u2013671. https:\/\/doi.org\/10.1016\/j.nmd.2022.06.006","journal-title":"Neuromuscul Disord"},{"key":"8964_CR70","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.nmd.2016.12.004","volume":"27","author":"V Afanasiev","year":"2017","unstructured":"Afanasiev V, Demeret S, Bolgert F et al (2017) Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients. Neuromuscul Disord 27:251\u2013258. https:\/\/doi.org\/10.1016\/j.nmd.2016.12.004","journal-title":"Neuromuscul Disord"},{"key":"8964_CR71","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1212\/CPJ.0000000000000202","volume":"6","author":"KM Kanth","year":"2016","unstructured":"Kanth KM, Solorzano GE, Goldman MD (2016) PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. Neurol Clin Pract 6:e17\u2013e19. https:\/\/doi.org\/10.1212\/CPJ.0000000000000202","journal-title":"Neurol Clin Pract"},{"key":"8964_CR72","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3899\/jrheum.180784","volume":"46","author":"KA Papp","year":"2019","unstructured":"Papp KA, Haraoui B, Kumar D et al (2019) Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. J Rhuematol 46:751\u2013754. https:\/\/doi.org\/10.3899\/jrheum.180784","journal-title":"J Rhuematol"},{"key":"8964_CR73","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1111\/ene.15809","volume":"30","author":"S Otero-Romero","year":"2023","unstructured":"Otero-Romero S, Lebrun-Fr\u00e9nay C, Reyes S et al (2023) European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Eur J Neurol 30:2144\u20132176. https:\/\/doi.org\/10.1111\/ene.15809","journal-title":"Eur J Neurol"},{"key":"8964_CR74","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Levin MJ, Ljungman P et al (2014) Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis 58:309\u2013318. https:\/\/doi.org\/10.1093\/cid\/cit816","journal-title":"Clin Infect Dis"},{"key":"8964_CR75","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/14737175.2023.2178302","volume":"23","author":"NE Gilhus","year":"2023","unstructured":"Gilhus NE (2023) Treatment considerations in myasthenia gravis for the pregnant patient. Expert Rev Neurother 23:169\u2013177. https:\/\/doi.org\/10.1080\/14737175.2023.2178302","journal-title":"Expert Rev Neurother"},{"key":"8964_CR76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501561","author":"RJ Nowak","year":"2025","unstructured":"Nowak RJ, Benatar M, Ciafaloni E et al (2025) A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2501561. NEJMoa2501561","journal-title":"N Engl J Med"},{"key":"8964_CR77","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/cells14100739","volume":"14","author":"A Martinez Salazar","year":"2025","unstructured":"Martinez Salazar A, Mokhtari S, Peguero E, Jaffer M (2025) The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis. Cells 14:739. https:\/\/doi.org\/10.3390\/cells14100739","journal-title":"Cells"},{"key":"8964_CR78","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00415-025-13225-7","volume":"272","author":"Y Wang","year":"2025","unstructured":"Wang Y, Nao J, Duan Y et al (2025) Therapeutic strategies targeting complement in myasthenia gravis patients. J Neurol 272:489. https:\/\/doi.org\/10.1007\/s00415-025-13225-7","journal-title":"J Neurol"},{"key":"8964_CR79","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/acn3.51121","volume":"7","author":"R Mantegazza","year":"2020","unstructured":"Mantegazza R, O\u2019Brien FL, Yountz M et al (2020) Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Ann Clin Transl Neurol 7:1327\u20131339. https:\/\/doi.org\/10.1002\/acn3.51121","journal-title":"Ann Clin Transl Neurol"},{"key":"8964_CR80","doi-asserted-by":"publisher","first-page":"556104","DOI":"10.3389\/fneur.2020.556104","volume":"11","author":"RJ Nowak","year":"2020","unstructured":"Nowak RJ, Muppidi S, Beydoun SR et al (2020) Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study. Front Neurol 11:556104. https:\/\/doi.org\/10.3389\/fneur.2020.556104","journal-title":"Front Neurol"},{"key":"8964_CR81","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M et al (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60:14\u201324. https:\/\/doi.org\/10.1002\/mus.26447","journal-title":"Muscle Nerve"},{"key":"8964_CR82","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40265-023-01877-6","volume":"83","author":"C Kang","year":"2023","unstructured":"Kang C (2023) Ravulizumab: A Review in Generalised Myasthenia Gravis. Drugs 83:717\u2013723. https:\/\/doi.org\/10.1007\/s40265-023-01877-6","journal-title":"Drugs"},{"key":"8964_CR83","doi-asserted-by":"publisher","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu Z-X, Zhang Y et al (2018) Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS ONE 13:e0195909. https:\/\/doi.org\/10.1371\/journal.pone.0195909","journal-title":"PLoS ONE"},{"key":"8964_CR84","doi-asserted-by":"publisher","unstructured":"Vu T, Meisel A, Mantegazza R et al (2022) Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. https:\/\/doi.org\/10.1056\/EVIDoa2100066. NEJM Evidence 1:","DOI":"10.1056\/EVIDoa2100066"},{"key":"8964_CR85","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","volume":"270","author":"A Meisel","year":"2023","unstructured":"Meisel A, Annane D, Vu T et al (2023) Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol 270:3862\u20133875. https:\/\/doi.org\/10.1007\/s00415-023-11699-x","journal-title":"J Neurol"},{"key":"8964_CR86","doi-asserted-by":"publisher","first-page":"175628642110019","DOI":"10.1177\/17562864211001995","volume":"14","author":"H Murai","year":"2021","unstructured":"Murai H, Suzuki S, Hasebe M et al (2021) Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance. Ther Adv Neurol Disord 14:17562864211001995. https:\/\/doi.org\/10.1177\/17562864211001995","journal-title":"Ther Adv Neurol Disord"},{"key":"8964_CR87","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/JND-200584","volume":"8","author":"N Katyal","year":"2021","unstructured":"Katyal N, Narula N, Govindarajan R (2021) Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. J Neuromuscul Dis 8:287\u2013294. https:\/\/doi.org\/10.3233\/JND-200584","journal-title":"J Neuromuscul Dis"},{"key":"8964_CR88","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/acn3.52051","volume":"11","author":"D Tokuyasu","year":"2024","unstructured":"Tokuyasu D, Suzuki S, Uzawa A et al (2024) Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. Ann Clin Transl Neurol 11:1338\u20131346. https:\/\/doi.org\/10.1002\/acn3.52051","journal-title":"Ann Clin Transl Neurol"},{"key":"8964_CR89","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s00415-025-13127-8","volume":"272","author":"E Rossini","year":"2025","unstructured":"Rossini E, Di Stefano V, Iorio R et al (2025) Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience. J Neurol 272:396. https:\/\/doi.org\/10.1007\/s00415-025-13127-8","journal-title":"J Neurol"},{"key":"8964_CR90","doi-asserted-by":"publisher","first-page":"e200331","DOI":"10.1212\/NXI.0000000000200331","volume":"12","author":"F Stascheit","year":"2024","unstructured":"Stascheit F, de Sousa CDF, Aigner A et al (2024) Ravulizumab and Efgartigimod in Myasthenia Gravis. Neurol Neuroimmunol Neuroinflamm 12:e200331. https:\/\/doi.org\/10.1212\/NXI.0000000000200331","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"8964_CR91","doi-asserted-by":"publisher","first-page":"175628642090420","DOI":"10.1177\/1756286420904207","volume":"13","author":"M Oyama","year":"2020","unstructured":"Oyama M, Okada K, Masuda M et al (2020) Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Ther Adv Neurol Disord 13:1756286420904207. https:\/\/doi.org\/10.1177\/1756286420904207","journal-title":"Ther Adv Neurol Disord"},{"key":"8964_CR92","doi-asserted-by":"publisher","first-page":"109011","DOI":"10.1016\/j.clineuro.2025.109011","volume":"256","author":"E Rossini","year":"2025","unstructured":"Rossini E, Morino S, Garibaldi M et al (2025) Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how. Clin Neurol Neurosurg 256:109011. https:\/\/doi.org\/10.1016\/j.clineuro.2025.109011","journal-title":"Clin Neurol Neurosurg"},{"key":"8964_CR93","doi-asserted-by":"publisher","first-page":"1562419","DOI":"10.3389\/fimmu.2025.1562419","volume":"16","author":"S Marini","year":"2025","unstructured":"Marini S, Erra C, Fionda L et al (2025) Complement inhibitor therapy in thymoma-associated myasthenia gravis: a real-world experience. Front Immunol 16:1562419. https:\/\/doi.org\/10.3389\/fimmu.2025.1562419","journal-title":"Front Immunol"},{"key":"8964_CR94","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1007\/s00415-024-12234-2","volume":"271","author":"FF Konen","year":"2024","unstructured":"Konen FF, Jendretzky KF, Ratuszny D et al (2024) Ravulizumab in myasthenic crisis: the first case report. J Neurol 271:2898\u20132901. https:\/\/doi.org\/10.1007\/s00415-024-12234-2","journal-title":"J Neurol"},{"key":"8964_CR95","doi-asserted-by":"publisher","first-page":"e200177","DOI":"10.1212\/NXI.0000000000200177","volume":"11","author":"C Nelke","year":"2024","unstructured":"Nelke C, Pawlitzki M, Kerkhoff R et al (2024) Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade. Neurol Neuroimmunol Neuroinflamm 11:e200177. https:\/\/doi.org\/10.1212\/NXI.0000000000200177","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"8964_CR96","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s10072-023-07190-0","volume":"45","author":"L Fionda","year":"2024","unstructured":"Fionda L, Rossini E, Lauletta A et al (2024) Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors. Neurol Sci 45:1243\u20131247. https:\/\/doi.org\/10.1007\/s10072-023-07190-0","journal-title":"Neurol Sci"},{"key":"8964_CR97","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/mus.28037","volume":"69","author":"S Zadeh","year":"2024","unstructured":"Zadeh S, Price H, Drews R et al (2024) Novel uses of complement inhibitors in myasthenia gravis-Two case reports. Muscle Nerve 69:368\u2013372. https:\/\/doi.org\/10.1002\/mus.28037","journal-title":"Muscle Nerve"},{"key":"8964_CR98","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1007\/s10072-024-07972-0","volume":"46","author":"A Rigamonti","year":"2025","unstructured":"Rigamonti A, Mantero V, Milani R, Salmaggi A (2025) Eculizumab as rescue therapy for relapse of myasthenia gravis after immune-checkpoint inhibitors: a case report. Neurol Sci 46:2893\u20132896. https:\/\/doi.org\/10.1007\/s10072-024-07972-0","journal-title":"Neurol Sci"},{"key":"8964_CR99","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000511957","volume":"13","author":"T Vu","year":"2021","unstructured":"Vu T, Harvey B, Suresh N et al (2021) Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report. Case Rep Neurol 13:65\u201372. https:\/\/doi.org\/10.1159\/000511957","journal-title":"Case Rep Neurol"},{"key":"8964_CR100","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1017\/cjn.2022.278","volume":"50","author":"X Li","year":"2023","unstructured":"Li X, Mehrabyan A (2023) Managing Myasthenia Gravis with Eculizumab Monotherapy Through Pregnancy. Can J Neurol Sci 50:803\u2013805. https:\/\/doi.org\/10.1017\/cjn.2022.278","journal-title":"Can J Neurol Sci"},{"key":"8964_CR101","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1182\/blood-2024-209857","volume":"144","author":"B Hoechsmann","year":"2024","unstructured":"Hoechsmann B, Leopold W, Schneider A et al (2024) Ravulizumab in Pregnant Women with Paroxysmal Nocturnal Hemoglobinuria (PNH) - Favourable Experience from a Retrospective Case Series. Blood 144:5251. https:\/\/doi.org\/10.1182\/blood-2024-209857","journal-title":"Blood"},{"key":"8964_CR102","doi-asserted-by":"publisher","first-page":"696385","DOI":"10.3389\/fneur.2021.696385","volume":"12","author":"JPR Monteleone","year":"2021","unstructured":"Monteleone JPR, Gao X, Kleijn HJ et al (2021) Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis. Front Neurol 12:696385. https:\/\/doi.org\/10.3389\/fneur.2021.696385","journal-title":"Front Neurol"},{"key":"8964_CR103","doi-asserted-by":"publisher","first-page":"1213920","DOI":"10.3389\/fimmu.2023.1213920","volume":"14","author":"G-Q Tang","year":"2023","unstructured":"Tang G-Q, Tang Y, Dhamnaskar K et al (2023) Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation. Front Immunol 14:1213920. https:\/\/doi.org\/10.3389\/fimmu.2023.1213920","journal-title":"Front Immunol"},{"key":"8964_CR104","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/13543784.2021.1897567","volume":"30","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr., Vissing J, Gilhus NE et al (2021) Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody\u2013Positive Generalized Myasthenia Gravis. Expert Opin Investig Drugs 30:483\u2013493. https:\/\/doi.org\/10.1080\/13543784.2021.1897567","journal-title":"Expert Opin Investig Drugs"},{"key":"8964_CR105","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","volume":"370","author":"J Nishimura","year":"2014","unstructured":"Nishimura J, Yamamoto M, Hayashi S et al (2014) Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370:632\u2013639. https:\/\/doi.org\/10.1056\/NEJMoa1311084","journal-title":"N Engl J Med"},{"key":"8964_CR106","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-025-02860-6","author":"A Maruani","year":"2025","unstructured":"Maruani A, Demeret S, Piljan M et al (2025) Zilucoplan in myasthenic crisis refractory to conventional treatment: a report of two cases. Acta Neurol Belg. https:\/\/doi.org\/10.1007\/s13760-025-02860-6","journal-title":"Acta Neurol Belg"},{"key":"8964_CR107","doi-asserted-by":"publisher","first-page":"e80203","DOI":"10.7759\/cureus.80203","volume":"17","author":"S Ito","year":"2025","unstructured":"Ito S, Sugimoto T, Naito H et al (2025) Zilucoplan for Successful Early Weaning From Mechanical Ventilation and Avoiding Tracheostomy in an 85-Year-Old Woman Experiencing Myasthenic Crisis: A Case Report. Cureus 17:e80203. https:\/\/doi.org\/10.7759\/cureus.80203","journal-title":"Cureus"},{"key":"8964_CR108","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00415-025-13113-0","volume":"272","author":"C Hewamadduma","year":"2025","unstructured":"Hewamadduma C, Freimer M, Genge A et al (2025) Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis. J Neurol 272:457. https:\/\/doi.org\/10.1007\/s00415-025-13113-0","journal-title":"J Neurol"},{"key":"8964_CR109","doi-asserted-by":"publisher","first-page":"175628642412431","DOI":"10.1177\/17562864241243186","volume":"17","author":"F James","year":"2024","unstructured":"James F, Howard J, Bresch S, Farmakidis C et al (2024) Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study. Ther Adv Neurol Disord 17:17562864241243186. https:\/\/doi.org\/10.1177\/17562864241243186","journal-title":"Ther Adv Neurol Disord"},{"key":"8964_CR110","doi-asserted-by":"publisher","first-page":"175628642513472","DOI":"10.1177\/17562864251347283","volume":"18","author":"M Freimer","year":"2025","unstructured":"Freimer M, Desai U, Govindarajan R et al (2025) Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study. Ther Adv Neurol Disord 18:17562864251347283. https:\/\/doi.org\/10.1177\/17562864251347283","journal-title":"Ther Adv Neurol Disord"},{"key":"8964_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.125671","volume":"479","author":"V Di Stefano","year":"2025","unstructured":"Di Stefano V, Rini N, Antozzi C et al (2025) Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study. J Neurol Sci 479:125671. https:\/\/doi.org\/10.1016\/j.jns.2025.125671","journal-title":"J Neurol Sci"},{"key":"8964_CR112","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMra2312718","volume":"392","author":"JB Bussel","year":"2025","unstructured":"Bussel JB, Cines DB, Blumberg RS (2025) Neonatal Fc receptor \u2014 biology and therapeutics. N Engl J Med 392:1621\u20131635. https:\/\/doi.org\/10.1056\/NEJMra2312718","journal-title":"N Engl J Med"},{"key":"8964_CR113","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381","volume":"14","author":"MC Dalakas","year":"2021","unstructured":"Dalakas MC, Spaeth PJ (2021) The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord 14:1756286421997381. https:\/\/doi.org\/10.1177\/1756286421997381","journal-title":"Ther Adv Neurol Disord"},{"key":"8964_CR114","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semarthrit.2008.05.002","volume":"39","author":"DE Furst","year":"2009","unstructured":"Furst DE (2009) Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 39:18\u201329. https:\/\/doi.org\/10.1016\/j.semarthrit.2008.05.002","journal-title":"Semin Arthritis Rheum"},{"key":"8964_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01540","volume":"10","author":"M Pyzik","year":"2019","unstructured":"Pyzik M, Sand KMK, Hubbard JJ et al (2019) The neonatal Fc receptor (FcRn): a misnomer? Front Immunol 10:1540. https:\/\/doi.org\/10.3389\/fimmu.2019.01540","journal-title":"Front Immunol"},{"key":"8964_CR116","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T et al (2018) Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest 128:4372\u20134386. https:\/\/doi.org\/10.1172\/JCI97911","journal-title":"J Clin Invest"},{"key":"8964_CR117","doi-asserted-by":"publisher","first-page":"1284444","DOI":"10.3389\/fneur.2023.1284444","volume":"14","author":"JF Howard","year":"2023","unstructured":"Howard JF, Bril V, Vu T et al (2023) Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. Front Neurol 14:1284444. https:\/\/doi.org\/10.3389\/fneur.2023.1284444","journal-title":"Front Neurol"},{"key":"8964_CR118","doi-asserted-by":"publisher","first-page":"e00378","DOI":"10.1016\/j.neurot.2024.e00378","volume":"21","author":"JF Howard","year":"2024","unstructured":"Howard JF, Vu T, Li G et al (2024) Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+). Neurotherapeutics 21:e00378. https:\/\/doi.org\/10.1016\/j.neurot.2024.e00378","journal-title":"Neurotherapeutics"},{"key":"8964_CR119","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/acn3.70051","volume":"12","author":"AA Habib","year":"2025","unstructured":"Habib AA, Claeys KG, Bril V et al (2025) ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia Gravis. Ann Clin Transl Neurol 12:1162\u20131170. https:\/\/doi.org\/10.1002\/acn3.70051","journal-title":"Ann Clin Transl Neurol"},{"key":"8964_CR120","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/1744666X.2025.2497840","volume":"21","author":"KG Gwathmey","year":"2025","unstructured":"Gwathmey KG, Broome CM, Goebeler M et al (2025) Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases. Expert Rev Clin Immunol 21:627\u2013638. https:\/\/doi.org\/10.1080\/1744666X.2025.2497840","journal-title":"Expert Rev Clin Immunol"},{"key":"8964_CR121","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/mus.28003","volume":"69","author":"M Singer","year":"2024","unstructured":"Singer M, Khella S, Bird S et al (2024) Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events. Muscle Nerve 69:87\u201392. https:\/\/doi.org\/10.1002\/mus.28003","journal-title":"Muscle Nerve"},{"key":"8964_CR122","doi-asserted-by":"publisher","first-page":"e16189","DOI":"10.1111\/ene.16189","volume":"31","author":"R Frangiamore","year":"2024","unstructured":"Frangiamore R, Rinaldi E, Vanoli F et al (2024) Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center. Eur J Neurol 31:e16189. https:\/\/doi.org\/10.1111\/ene.16189","journal-title":"Eur J Neurol"},{"key":"8964_CR123","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang Q, Zeng W et al (2024) Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China. Ann Clin Transl Neurol 11:2212\u20132221. https:\/\/doi.org\/10.1002\/acn3.52142","journal-title":"Ann Clin Transl Neurol"},{"key":"8964_CR124","doi-asserted-by":"publisher","first-page":"578431","DOI":"10.1016\/j.jneuroim.2024.578431","volume":"395","author":"Y Hong","year":"2024","unstructured":"Hong Y, Gao L, Huang S-Q et al (2024) Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series. J Neuroimmunol 395:578431. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578431","journal-title":"J Neuroimmunol"},{"key":"8964_CR125","doi-asserted-by":"publisher","first-page":"1321058","DOI":"10.3389\/fneur.2024.1321058","volume":"15","author":"K Watanabe","year":"2024","unstructured":"Watanabe K, Ohashi S, Watanabe T et al (2024) Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod. Front Neurol 15:1321058. https:\/\/doi.org\/10.3389\/fneur.2024.1321058","journal-title":"Front Neurol"},{"key":"8964_CR126","doi-asserted-by":"publisher","first-page":"28394","DOI":"10.1038\/s41598-024-79918-7","volume":"14","author":"J Ma","year":"2024","unstructured":"Ma J, Zhang H, Zhao J et al (2024) Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis. Sci Rep 14:28394. https:\/\/doi.org\/10.1038\/s41598-024-79918-7","journal-title":"Sci Rep"},{"key":"8964_CR127","doi-asserted-by":"publisher","first-page":"175628642513196","DOI":"10.1177\/17562864251319656","volume":"18","author":"L Jin","year":"2025","unstructured":"Jin L, Zou Z, Wang Q et al (2025) Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes. Ther Adv Neurol Disord 18:17562864251319656. https:\/\/doi.org\/10.1177\/17562864251319656","journal-title":"Ther Adv Neurol Disord"},{"key":"8964_CR128","doi-asserted-by":"publisher","first-page":"1579859","DOI":"10.3389\/fimmu.2025.1579859","volume":"16","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Yang M, Guo X et al (2025) Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis. Front Immunol 16:1579859. https:\/\/doi.org\/10.3389\/fimmu.2025.1579859","journal-title":"Front Immunol"},{"key":"8964_CR129","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.jtho.2025.04.014","volume":"20","author":"S Wang","year":"2025","unstructured":"Wang S, Zhu M, Dong J et al (2025) Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial. J Thorac Oncol 20:1120\u20131130. https:\/\/doi.org\/10.1016\/j.jtho.2025.04.014","journal-title":"J Thorac Oncol"},{"key":"8964_CR130","doi-asserted-by":"publisher","first-page":"e200276","DOI":"10.1212\/CPJ.0000000000200276","volume":"14","author":"S Suzuki","year":"2024","unstructured":"Suzuki S, Uzawa A, Nagane Y et al (2024) Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan. Neurol Clin Pract 14:e200276. https:\/\/doi.org\/10.1212\/CPJ.0000000000200276","journal-title":"Neurol Clin Pract"},{"key":"8964_CR131","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00415-023-11970-1","volume":"271","author":"V Di Stefano","year":"2024","unstructured":"Di Stefano V, Alonge P, Rini N et al (2024) Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome. J Neurol 271:254\u2013262. https:\/\/doi.org\/10.1007\/s00415-023-11970-1","journal-title":"J Neurol"},{"key":"8964_CR132","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/22143602241308181","volume":"12","author":"AA Habib","year":"2025","unstructured":"Habib AA, Dru\u017cd\u017c A, Grosskreutz J et al (2025) Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension. J Neuromuscul Dis 12:231\u2013243. https:\/\/doi.org\/10.1177\/22143602241308181","journal-title":"J Neuromuscul Dis"},{"key":"8964_CR133","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00415-025-12958-9","volume":"272","author":"V Bril","year":"2025","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J et al (2025) Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. J Neurol 272:275. https:\/\/doi.org\/10.1007\/s00415-025-12958-9","journal-title":"J Neurol"},{"key":"8964_CR134","doi-asserted-by":"publisher","first-page":"175628642412730","DOI":"10.1177\/17562864241273036","volume":"17","author":"AA Habib","year":"2024","unstructured":"Habib AA, Sacconi S, Antonini G et al (2024) Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Ther Adv Neurol Disord 17:17562864241273036. https:\/\/doi.org\/10.1177\/17562864241273036","journal-title":"Ther Adv Neurol Disord"},{"key":"8964_CR135","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s00415-025-13420-6","volume":"272","author":"V Bril","year":"2025","unstructured":"Bril V, Antozzi C, Berkowicz T et al (2025) Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study. J Neurol 272:686. https:\/\/doi.org\/10.1007\/s00415-025-13420-6","journal-title":"J Neurol"},{"key":"8964_CR136","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","volume":"24","author":"C Antozzi","year":"2025","unstructured":"Antozzi C, Vu T, Ramchandren S et al (2025) Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol 24:105\u2013116. https:\/\/doi.org\/10.1016\/S1474-4422(24)00498-8","journal-title":"Lancet Neurol"},{"key":"8964_CR137","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/apt.70188","volume":"62","author":"S Flatley","year":"2025","unstructured":"Flatley S, Dixon S, Pilsworth E et al (2025) Diabetes Mellitus in Patients With Autoimmune Hepatitis: Frequency, Risk Factors and Effect on Outcome. Aliment Pharmacol Ther 62:319\u2013329. https:\/\/doi.org\/10.1111\/apt.70188","journal-title":"Aliment Pharmacol Ther"},{"key":"8964_CR138","first-page":"126","volume":"32","author":"TP Angelopoulos","year":"2014","unstructured":"Angelopoulos TP, Tentolouris NK, Bertsias GK, Boumpas DT (2014) Steroid-induced diabetes in rheumatologic patients. Clin Exp Rheumatol 32:126\u2013130","journal-title":"Clin Exp Rheumatol"},{"key":"8964_CR139","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/B978-0-12-823912-4.00026-8","volume":"200","author":"MR Tannemaat","year":"2024","unstructured":"Tannemaat MR, Huijbers MG, Verschuuren JJGM (2024) Myasthenia gravis-Pathophysiology, diagnosis, and treatment. Handb Clin Neurol 200:283\u2013305. https:\/\/doi.org\/10.1016\/B978-0-12-823912-4.00026-8","journal-title":"Handb Clin Neurol"},{"key":"8964_CR140","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/TP.0b013e31826e592e","volume":"95","author":"HA Chakkera","year":"2013","unstructured":"Chakkera HA, Mandarino LJ (2013) Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation 95:647\u2013652. https:\/\/doi.org\/10.1097\/TP.0b013e31826e592e","journal-title":"Transplantation"},{"key":"8964_CR141","volume-title":"Steroid-Induced Glaucoma","author":"KB Feroze","year":"2025","unstructured":"Feroze KB, Zeppieri M, Khazaeni L (2025) Steroid-Induced Glaucoma. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"8964_CR142","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/jcm10071537","volume":"10","author":"S Sheikh","year":"2021","unstructured":"Sheikh S, Alvi U, Soliven B, Rezania K (2021) Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update. J Clin Med 10:1537. https:\/\/doi.org\/10.3390\/jcm10071537","journal-title":"J Clin Med"},{"key":"8964_CR143","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1002\/acr.25240","volume":"75","author":"MB Humphrey","year":"2023","unstructured":"Humphrey MB, Russell L, Danila MI et al (2023) 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken) 75:2405\u20132419. https:\/\/doi.org\/10.1002\/acr.25240","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8964_CR144","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1007\/s00467-023-05969-z","volume":"38","author":"K Kamei","year":"2023","unstructured":"Kamei K (2023) Live attenuated vaccines in patients receiving immunosuppressive agents. Pediatr Nephrol 38:3889\u20133900. https:\/\/doi.org\/10.1007\/s00467-023-05969-z","journal-title":"Pediatr Nephrol"},{"key":"8964_CR145","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1007\/s00415-022-11140-9","volume":"269","author":"G Sansone","year":"2022","unstructured":"Sansone G, Bonifati DM (2022) Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients. J Neurol 269:3965\u20133981. https:\/\/doi.org\/10.1007\/s00415-022-11140-9","journal-title":"J Neurol"},{"key":"8964_CR146","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3390\/vaccines11030516","volume":"11","author":"JD Altman","year":"2023","unstructured":"Altman JD, Miner DS, Lee AA et al (2023) Factors Affecting Vaccine Attitudes Influenced by the COVID-19 Pandemic. Vaccines (Basel) 11:516. https:\/\/doi.org\/10.3390\/vaccines11030516","journal-title":"Vaccines (Basel)"},{"key":"8964_CR147","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acr.25045","volume":"75","author":"AR Bass","year":"2023","unstructured":"Bass AR, Chakravarty E, Akl EA et al (2023) 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken) 75:449\u2013464. https:\/\/doi.org\/10.1002\/acr.25045","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8964_CR148","doi-asserted-by":"publisher","first-page":"2263979","DOI":"10.1080\/21645515.2023.2263979","volume":"19","author":"R Parikh","year":"2023","unstructured":"Parikh R, Singer D, Chmielewski-Yee E, Dessart C (2023) Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence. Hum Vaccin Immunother 19:2263979. https:\/\/doi.org\/10.1080\/21645515.2023.2263979","journal-title":"Hum Vaccin Immunother"},{"key":"8964_CR149","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/ene.15348","volume":"29","author":"A Farina","year":"2022","unstructured":"Farina A, Falso S, Cornacchini S et al (2022) Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience. Eur J Neurol 29:2505\u20132510. https:\/\/doi.org\/10.1111\/ene.15348","journal-title":"Eur J Neurol"},{"key":"8964_CR150","doi-asserted-by":"publisher","first-page":"578215","DOI":"10.1016\/j.jneuroim.2023.578215","volume":"384","author":"S Holm-Yildiz","year":"2023","unstructured":"Holm-Yildiz S, Dysgaard T, Krag T et al (2023) Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis. J Neuroimmunol 384:578215. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578215","journal-title":"J Neuroimmunol"},{"key":"8964_CR151","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.nmd.2023.02.005","volume":"33","author":"V Damato","year":"2023","unstructured":"Damato V, Spagni G, Monte G et al (2023) Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab. Neuromuscul Disord 33:288\u2013294. https:\/\/doi.org\/10.1016\/j.nmd.2023.02.005","journal-title":"Neuromuscul Disord"},{"key":"8964_CR152","doi-asserted-by":"publisher","DOI":"10.1186\/ar3047","volume":"12","author":"M Rehnberg","year":"2010","unstructured":"Rehnberg M, Brisslert M, Amu S et al (2010) Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther 12:R111. https:\/\/doi.org\/10.1186\/ar3047","journal-title":"Arthritis Res Ther"},{"key":"8964_CR153","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1002\/art.42541","volume":"75","author":"JW Park","year":"2023","unstructured":"Park JW, Curtis JR, Choi SR et al (2023) Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab. Arthritis Rheumatol 75:2036\u20132044. https:\/\/doi.org\/10.1002\/art.42541","journal-title":"Arthritis Rheumatol"},{"key":"8964_CR154","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/mus.28328","volume":"71","author":"C Bacher","year":"2025","unstructured":"Bacher C, Narayanswami P, Bromberg M et al (2025) International consensus guidance for the management of glucocorticoid related complications in neuromuscular disease. Muscle Nerve 71:309\u2013316. https:\/\/doi.org\/10.1002\/mus.28328","journal-title":"Muscle Nerve"},{"key":"8964_CR155","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","volume":"168","author":"FS Ali","year":"2025","unstructured":"Ali FS, Nguyen MH, Hernaez R et al (2025) AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals. Gastroenterology 168:267\u2013284. https:\/\/doi.org\/10.1053\/j.gastro.2024.11.008","journal-title":"Gastroenterology"},{"key":"8964_CR156","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP et al (2015) American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. Gastroenterology 148:215\u2013219. https:\/\/doi.org\/10.1053\/j.gastro.2014.10.039","journal-title":"Gastroenterology"},{"key":"8964_CR157","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Soci\u00e9","year":"2019","unstructured":"Soci\u00e9 G, Caby-Tosi M-P, Marantz JL et al (2019) Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol 185:297\u2013310. https:\/\/doi.org\/10.1111\/bjh.15790","journal-title":"Br J Haematol"},{"key":"8964_CR158","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jinf.2018.10.015","volume":"78","author":"PE Crew","year":"2019","unstructured":"Crew PE, McNamara L, Waldron PE et al (2019) Unusual Neisseria species as a cause of infection in patients taking eculizumab. J Infect 78:113\u2013118. https:\/\/doi.org\/10.1016\/j.jinf.2018.10.015","journal-title":"J Infect"},{"key":"8964_CR159","doi-asserted-by":"publisher","first-page":"ofad159","DOI":"10.1093\/ofid\/ofad159","volume":"10","author":"O Lortholary","year":"2023","unstructured":"Lortholary O, El-Sissy C, Leporrier J et al (2023) Disseminated Cryptococcosis Following Eculizumab Therapy: Insight Into Pathogenesis. Open Forum Infect Dis 10:ofad159. https:\/\/doi.org\/10.1093\/ofid\/ofad159","journal-title":"Open Forum Infect Dis"},{"key":"8964_CR160","doi-asserted-by":"publisher","first-page":"117955652199236","DOI":"10.1177\/1179556521992367","volume":"15","author":"PS Bicoll","year":"2021","unstructured":"Bicoll PS, Goyal A, Blatt NB, Freij BJ (2021) Eculizumab-Associated Moraxella lacunata Bacteremia and Systemic Inflammatory Response Syndrome in a Toddler with Atypical Hemolytic Uremic Syndrome. Clin Med Insights Pediatr 15:1179556521992367. https:\/\/doi.org\/10.1177\/1179556521992367","journal-title":"Clin Med Insights Pediatr"},{"key":"8964_CR161","doi-asserted-by":"publisher","first-page":"101013","DOI":"10.1016\/j.blre.2022.101013","volume":"58","author":"C Girmenia","year":"2023","unstructured":"Girmenia C, Barcellini W, Bianchi P et al (2023) Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs. Blood Rev 58:101013. https:\/\/doi.org\/10.1016\/j.blre.2022.101013","journal-title":"Blood Rev"},{"key":"8964_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","volume":"69","author":"SA Mbaeyi","year":"2020","unstructured":"Mbaeyi SA, Bozio CH, Duffy J et al (2020) Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 69:1\u201341. https:\/\/doi.org\/10.15585\/mmwr.rr6909a1","journal-title":"MMWR Recomm Rep"},{"key":"8964_CR163","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jbspin.2010.09.016","volume":"78","author":"M Samson","year":"2011","unstructured":"Samson M, Audia S, Lakomy D et al (2011) Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. Joint Bone Spine 78:241\u2013245. https:\/\/doi.org\/10.1016\/j.jbspin.2010.09.016","journal-title":"Joint Bone Spine"},{"key":"8964_CR164","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fimmu.2014.00626","volume":"5","author":"N Compagno","year":"2014","unstructured":"Compagno N, Malipiero G, Cinetto F, Agostini C (2014) Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol 5:626. https:\/\/doi.org\/10.3389\/fimmu.2014.00626","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.1007\/s10072-026-09058-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000}}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08964-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-08964-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08964-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:12:43Z","timestamp":1778292763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-08964-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":164,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["8964"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-08964-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\"The original online version of this article was revised: In the original version of this manuscript, the antibiotic prophylaxis shown in the grey box in Table 2 was captured as normal text. This should be captured and presented in the same way as in the original table, as it reflects the correct timing of antibiotic administration in relation to vaccine administration, as specified in the text (\u201cProphylaxis with penicillin or amoxicillin from treatment start to 15 days after the second vaccine dose\u201d).","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10072-026-09058-5","URL":"https:\/\/doi.org\/10.1007\/s10072-026-09058-5","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Specific national laws was observed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"LF received financial support from Alexion Pharmaceuticals, argenx, UCB, Dianthus, Johnson & Johnson and amgen. PEA received financial support from Alexion Pharmaceuticals, argenx, UCB. CA received funding for travel, meeting attendance and advisory board participation from argenx, Alexion, UCB and Johnson & Johnson. DMB received honoraria for Advisory board: Argenx, Alexion, Roche. Research support as PI for Roche and Alexion. Speaker\u2019s Honoraria from Argenx, Alexion, UCB. VD has received public speaking honoraria and compensation for advisory boards and\/or consultations fees from UCB, Argenx, Amgen, Alexion Pharmaceuticals, Dianthus, Roche. FH has received financial support from Abvie, Alexion Pharmaceuticals, Alnylam, Amgen, Angelini, Argenx, Alfa Sigma, Behring, Ipsen, Lusofarma, Merck, Roche, Takeda, UCB, and Johnson & Johnson. MI has received financial support from Alexion Pharmaceuticals, argenx, Regeneron and Johnson & Johnson. RI has received speaker honoraria from Alexion, Argenx, Johnson & Johnson, Merck, The Sumaira Foundation, and UCB, and has participated in advisory boards for Alexion, Amgen, Argenx, Dianthus Therapeutics, Johnson & Johnson, Merck, and UCB. RL received funding from MAYA IDEE SUD s.r.l.; ISS; QbGROUP s.r.l.; Symposium s.r.l.; Accademia Nazionale Di Medicina; AIM Italy s.r.l.; argenx; ARISTEA International s.r.l.; Clinical Learning s.r.l.; Takeda; UCB Pharma S.p.A.; first class s.r.l.; janssen-cilag S.p.A.; Amgen s.r.l.; Alfasigma S.p.A.; MATERIA PRIMA s.r.l. MMT has received financial support from Alexion Pharmaceuticals, argenx, UCB, Dianthus, Regeneron, Idorsia and Johnson & Johnson. LM has received honoraria for speaking, advisory boards, and compensation for congress participations from Sanofi, Roche, Biogen, Amicus Therapeutics, Alexion, Argenx, UCB, Johnson & Johnson, and Lupin, outside the submitted work. LM also received funding for fellowship from Biogen and Alexion. ReM received funding for Travel, Meeting attendance or Advisory Board participation from Alexion, Argenx, Biomarin, Catalyst, SANOFI, Regeneron and UCB. RoM has received financial support from Alexion, Johnson & Johnson, UCB, Merck. EP acknowledges payments or honoraria for lectures, presentations, speakers bureaus, or educational events from Biogen and Roche; support for attending meetings and\/or travels from Roche, Biogen, and Alexion; payments for participation on Advisory Board from Alexion, Santhera, UCB Biopharma, and Sanofi. MP has nothing to disclose. CR has received financial support for advisory boards and sponsorship for congresses from Alexion, Argenx, Amgen, Johnson & Johnson, UCB Pharma. GA received conference honoraria, advisory board and travel grants from Kedrion, Alnylam, Alexion, Argenx, Takeda. AE received honoraria for scientific award jury member (Grifols), speaker (UCB) and advisory board participation (Dianthus).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"353"}}